Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.77 |
| ▸ | CASP2 | P42575 | 1/20 | 0.69 |
| ▸ | NAAA | Q02083 | 1/20 | 0.65 |
| ▸ | THRA | P10827 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 5/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5164631 | 1.00 | DNM1 (0.77) | DNM1CASP2NAAATHRATHRB | |
| SCHEMBL4848780 | 1.00 | DNM1 (0.77) | DNM1CASP2NAAATHRATHRB | |
| SCHEMBL18402532 | 1.00 | DNM1 (0.77) | DNM1CASP2NAAATHRATHRB | |
| SCHEMBL9664334 | 1.00 | DNM1 (0.77) | DNM1CASP2NAAATHRATHRB | |
| SCHEMBL12344052 | 0.98 | DNM1 (0.74) | DNM1CASP2NAAATHRATHRB | |
| SCHEMBL14907185 | 0.92 | DNM1 (0.71) | DNM1CASP2NAAATHRATHRB | |
| SCHEMBL24412648 | 0.92 | DNM1 (0.65) | DNM1CASP2NAAATHRATHRB | |
| SCHEMBL18402531 | 0.91 | DNM1 (0.87) | DNM1CASP2NAAATHRATHRB | |
| SCHEMBL21827799 | 0.91 | DNM1 (0.87) | DNM1CASP2NAAATHRATHRB | |
| SCHEMBL21826891 | 0.91 | DNM1 (0.81) | DNM1CASP2NAAATHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632918-B2 | Semi-synthetic glycopeptides with antibiotic activity | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1861115-A2 | SEMI-SYNTHETIC GLYCOPEPTIDES WITH ANTIBIOTIC ACTIVITY | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20060276623-A1 | Semi-synthetic glycopeptides with antibiotic activity | CHIRON CORPORATION | 2006-12-07 | — | — | US | disclosed |
| WO-2006093947-A2 | SEMI-SYNTHETIC GLYCOPEPTIDES WITH ANTIBIOTIC ACTIVITY | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276623-A1 | Semi-synthetic glycopeptides with antibiotic activity | FUT6, AAAS, O60361 | DNM1 4511/4885CASP2 2549/4885NAAA 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.